United States · Platforms & data · MarketBeat

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Published by MarketBeat · United States 1 h ago

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

The Motley Fool

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

Investing.com

US accuses government contractor of leaking classified info to girlfriend’s Substack

MarketWatch

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

TheStreet

Hooters closes 35-year-old location after shutting 55 restaurants

Yahoo Finance